1464PComparison of three different chemotherapy regimens for concomitant chemoradiotherapy in locally advanced non-small cell lung cancer

Abstract Background The optimal chemotherapy regimen for concurrent chemoradiation in locally advanced non-small cell lung cancer (NSCLC) remains unclear. Cisplatin-etoposide regimen related toxicity is high, weekly regimens have been investigating. We aimed to compare the efficacy and safety of different concurrent chemotherapy regimens in the context. Methods A total of 225 patients with locally advanced, unresectable stage III NSCLC included. Patients who treated with weekly docetaxel-platin (DP), paclitaxel-platin (PP) and standard dose etoposide-platin (EP) chemotherapy regimens were selected and divided to groups for the comparison of toxicity, response rate, progression free survival (PFS) and overall survival (OS) rates. Results There was statistically significant difference between overall response rate of each treatment groups (DP: 96,1%, PP: 94% and EP:76.7%, p  Table . 1464P Patients characteristics DP (N = 102) N(%) PP (N = 50) N(%) EP (N = 73) N(%) P Median age 61 64 58 0.038 Gender Male 93(91.2) 48(96) 64(87.7) 0.28 Histopathology Squamous cell 53(52) 31(62) 43(58.9) Stage IIIB-IIIC 65(63.7) 31(62) 41(56.2) 0.59 Conclusions When the weekly chemotherapy regimens were compared with the standard dose, our study demonstrated similar survival rates but better treatment response rates. Adverse events and toxicity rates were different and depending on the type of chemotherapy regimen used. Legal entity responsible for the study Abdurrahman Isikdogan. Funding Has not received any funding. Disclosure All authors have declared no conflicts of interest.